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arterial reconstruction: Clinical implications
Christopher D. Owens, MD, MSc, San Francisco, Calif
For patients with the most severe manifestations of lower extremity arterial occlusive disease, bypass surgery using
autogenous vein has been the most durable reconstruction. However, the incidence of bypass graft stenosis and graft
failure remains substantial and wholesale improvements in patency are lacking. One potential explanation is that stenosis
arises not only from over exuberant intimal hyperplasia, but also due to insufficient adaptation or remodeling of the vein
to the arterial environment. Although in vivo human studies are difficult to conduct, recent advances in imaging
technology have made possible a more comprehensive structural examination of vein bypass maturation. This review
summarizes recent translational efforts to understand the structural and functional properties of human vein grafts and
places it within the context of the rich existing literature of vein graft failure. ( J Vasc Surg 2010;51:736-46.)With the changing demographics of an aging popula-
tion and a near-epidemic of diabetes mellitus, the preva-
lence of peripheral arterial disease (PAD) now approaches
between 9 to 12 million Americans.1,2 Among established
treatments for advanced PAD, the autogenous vein bypass
graft has been both the clinical standard and the most
comprehensively studied revascularization strategy. Never-
theless, 30% to 50% of saphenous vein grafts fail during the
intermediate period from 1 to 18 months postimplanta-
tion. This period is the most active from a biologic stand-
point and the culprit lesion is intimal hyperplasia (IH). It is
clear that IH is universal to all implanted vein grafts but
why it becomes pernicious and progresses to clinical steno-
sis at some locations in some veins while others are relatively
spared is not clear. In addition, all vein grafts undergo
structural remodeling of the lumen and wall to some extent
during this same time period. Long-term patency of the
vein graft likely depends on adequate adaptation into
the arterial environment as well as a relative moderation in
the development of IH.
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736For well over 50 years, surgeon-scientists have studied
histopathologic changes in the vein after implantation,
developed animal models, documented efficacy of vein
bypass, and with the aid of modern biology techniques,
elucidated molecular signaling pathways involved in IH.
With the later, came the potential of genetic engineering of
the vein graft and the promise of improving patency
through novel therapeutics with specific molecular strate-
gies.3-5 For example, the PRoject of Ex-Vivo graft
ENgineering viaTransfection III (PREVENTIII)was a phase
III study employing an antisense DNA decoy molecule to
the transcription factor E2F. This randomized, placebo-
controlled, double blinded trial was specifically powered to
detect a significant difference in vein graft patency in a
cohort of over 1400 patients with critical limb ischemia
(CLI). In this contemporary study, the overall 1-year pri-
mary patency rate was 61% – a value that has not changed
for the past several decades.6 While this trial ultimately failed
to meet its primary efficacy endpoint, it underscored our lack
of understanding of the pathophysiology of vein graft failure
perhaps by underestimating the complexity and redundancy
in the molecular elements contributing to IH or neglecting
other potential variables such as remodeling.4,6
Advances in imaging technology during the last decade
such as high resolution ultrasound scans, 3-dimensional
magnetic resonance imaging (3D-MRI), and intravascular
ultrasound scans have greatly facilitated our ability to study
human vein bypass grafts in vivo.7,8 These modalities have
the ability to reliably resolve submillimeter structures.8-10
Serial changes in the vein graft structure and function can
be quantified and patterns of normal and abnormal adap-
tation can be discerned. Beyond luminal changes, wall
thickness can now be determined and mathematic models
constructed building on the rich existing experimental data
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the last 4 decades.
Herein, recent advances to better understand the
pathogenesis and subsequent evolution of vein graft failure
are outlined. Importantly, in vivo observations are empha-
sized and placed within a historic and a clinical context
whenever possible.
THE HUMAN SAPHENOUS VEIN AND THE
UNIVERSAL RESPONSE TO INJURY
The normal in vivo appearance of the human saphe-
nous vein is a light blue, thin-walled structure that easily
distends with minimal pressure. Unfortunately, many veins
used in bypass grafting have pre-existing lesions such as
endothelial damage, medial hypertrophy, or intimal thick-
ening which may give them a slightly sclerotic appear-
ance.11,12 This creates considerable variability in the nor-
mal (usable) range of vein wall thickness from 180 to 650
m.13 While severe changes render the vein unusable, the
impact of subtle pre-bypass morphologic changes on the
future development of vein graft stenosis is not known,
though decreased compliance has been shown to be asso-
ciated with early vein graft failure.14 The focal nature of
vein graft stenosis detected by surveillance ultrasound scan
studies suggests that predisposing lesions may exist in these
areas.15
Intimal hyperplasia was first described in veins by the
Nobel prize winning physician Alex Carrel in 1906 and is
generally regarded as the universal injury response to a
blood vessel: regardless of the injury or the vessel.16 It is
thought to be due to a proliferation of smooth muscle cells
(SMCs) which have undergone a phenotypic switch from a
quiescent, contractile phenotype to that of a synthetic
migratory phenotype. The source of the SMCs which con-
tribute to the intimal hyperplasia has long been thought to
be from themedia of the vessel wall but the identification of
graft-extrinsic cells such as periadventitial fibroblast or cir-
culating precursor cells has challenged this concept.17-22
Production of extracellular fibrous matrix and ground sub-
stance by synthetic SMCs leads to a progressive increase in
intimal and medial fibrosis, reduction in cellularity, and
overall stiffening of the vein graft which may subsequently
limit the graft’s ability to properly remodel in the arterial
circulation. The endothelial cells play a key role in the
regulation of intimal growth by a number of tonic growth-
inhibitory mechanisms.23,24 Endothelial cell loss or dam-
age markedly attenuates these growth modulating effects.
Biologic mediators are also involved.25 Liberated
growth factors from platelets lining the injured vessel wall,
infiltration of inflammatory cells through the permeable
endothelial cell layer, circulating inflammatory molecules,
and endothelial dysfunction are likely operative.26-28 The
platelet-endothelium interaction is emphasized by the ef-
fectiveness of platelet inhibitors in preventing the early and
late occlusion of vein grafts.29,30
The harvesting and preparation of the saphenous vein
for bypass surgery affords ample opportunity to impart
injury. Mechanical manipulation, valve lysis, pressure dis-tension, ischemia/reperfusion, devascularization and de-
nervation, and transposition into the arterial environment
contribute to the injury of the vein.31-33 A number of
intraoperative techniques have been employed in an at-
tempt to mitigate the venous injury. These include no-
touch harvesting technique, venous storage solutions such
as the University of Wisconsin solution, as well as placing
veins in the in situ configuration to theoretically decrease
manipulation and warm-ischemia time.34-38 In general, it is
felt that storage in a papaverine-treated, tissue culture
solution, gentle harvesting, and the use of controlled dis-
tension decreases endothelial injury and possibly subse-
quent IH formation.39
The causal relationship between arterial hemodynamics
and IH is well established and, in a sense, fulfills Koch’s
postulates. For example, Brody et al40 demonstrated that
veins transposed into the arterial circulation developed IH,
whereas those dissected and re-anastomosed to the venous
circulation did not. Experimental vein grafts explanted
from the arterial circulation and subsequently transferred
back to the venous circulation demonstrated regression of
IH.41-44 Finally, vein grafts placed in a low-flow, high-
resistance environment developed an exuberant IH re-
sponse that regressed once placed into a normal flow envi-
ronment.45 These experiments suggest that the cyclic
mechanical forces of the arterial circulation are sufficient
and necessary for the development of IH rather than simply
the injury of dissection.
Evidence from animal models consistently show that
the IH thickness of a vein graft varies inversely proportional
to the magnitude of shear stress across the endothelial cell
surface.45-53 In one study, vein grafts exposed to 50% less
shear stress had a 63% thicker intimal layer after 4 weeks.48
Vein grafts placed in conditions of high shear stress dem-
onstrated more endothelium-dependent relaxation sug-
gesting that higher shear stress favorably improved endo-
thelial function, possibly through increased nitric oxide
(NO) production.47,54,55
The kinetics of IH development have also been studied
in the rabbit and canine vein graft models.22,56 There is an
initial burst of endothelial and smooth muscle cell prolifer-
ation occurring within 1 week following implantation and a
return to the baseline quiescent state by week 12. More
recently, mathematical relationships of the temporal se-
quence of the development of IH as a function of shear
stress and time, h(t, )  ho  (RL[1-e
A(t-t*)])/
(1  BC), where h is the intimal thickness, t is time,  is
shear stress, ho is the intimal thickness at the time of
implantation, RL is the initial lumen radius, and t* is the
time when intimal thickness begins to change. A, B, and
C are experimentally derived constants and, therefore,
unique to the model used.57,58 The application of math-
ematical models of this type, validated in human vein
grafts, would be of great benefit in the determination of
efficacy of new therapeutics or biologics developed to
inhibit IH.
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CALIBER REGULATION
While much attention has been given to IH as the
primary mode of failure for vein grafts, relatively limited
information is available on the role remodeling plays in the
failing vein graft.6,7,10,59,60 Remodeling is defined as a
dynamic structural and biochemical adaptation within the
vein graft that results in long-term changes in lumen cali-
ber, wall thickness, composition of matrix proteins, and
endothelial cell reactivity.7,61-67 Remodeling is dependent
on an interaction between locally and remotely generated
growth factors, vasoactive substances, and hemodynamic
stimuli.22,68
It is well known that arteries undergo compensatory
remodeling in response to hemodynamic forces.69-75 The
resulting change in lumen caliber or wall thickness is
thought to maintain these forces at a biologically preset
value that promotes maximum efficiency of blood trans-
port.69,70 Between the predominant hemodynamic forces,
wall tension and shear stress, the later appears to be the
dominant of the two in regulating lumen caliber.76 While
blood flow is proportional to the product of the vessel’s
radius and the pressure gradient across the vessel, shear
stress is proportional to the quotient of blood flow and
lumen radius. Shear stress is the frictional force per unit area
tangential to the vessel wall and, therefore, “sensed” by
endothelial cells. Endothelial cells are the recognized bio-
sensor of the vessel and align themselves along the direction
of shear stress. Steady laminar shear stress has a healthy
trophic effect on the endothelial cells by inhibiting leuko-
cyte adhesion, promoting vasodilator production such as
NO77 and prostacyclin,78 limiting SMC hyperplasia,79 and
decreasing platelet aggregation.80 Conversely, low shear
stress and turbulence associated with complex geometries
such as anastomosis and valves, has the opposite effect.81
Removal of the endothelium abolishes flow-dependent
vasodilation.82
A vein implanted into the arterial circulation will expe-
rience a several-fold increase in both shear stress and wall
tension. Several lines of evidence argue that hemodynamic
regulation of venous structures exist.74,83-85 In a rabbit
jugular vein – carotid artery interposition model, the lumen
radius increased 57% over a 24-week study period: a mag-
nitude sufficient to reduce the initially high shear stress
down to that of a normal rabbit carotid artery.56 The
remarkable rapidity in which the vein remodels after im-
plantation in the arterial circulation was exemplified in a
canine model whereby maximal diameter was attained in
just 7 days.22
The ability for human saphenous vein grafts to dilate
substantially – and sometimes pathologically – after implan-
tation has been known from autopsy studies for nearly 50
years.86 Fillinger et al87 demonstrated that final lumen
diameter attained at 12 months was a function of the initial
lumen diameter and shear stress. While vein grafts, which
had the highest initial shear stress, tended to be smaller at
the time of implantation, they underwent greater lumendilation then those with lower initial shear stress. This
observation is important to consider when choosing to use
or discard a relatively small vein, as it is well known that the
luminal size of the vein is of primary importance for subse-
quent patency.88,89 However, a small vein, free of pre-
existing pathology, that is compliant and distends easily will
likely dilate and function well as a bypass graft.
More recently, quantification of human vein graft lu-
men remodeling has been assessed using a high-resolution
ultrasound scan. It has been shown that the vein graft
lumen, on average, dilates about 22% over the first 6
months of implantation (Fig 1, A).10 The most pro-
nounced period of luminal change was during the first 30
days. However, considerable variability existed in luminal
dilation (range, 31% to 64%) as evidenced by the fact
that a substantial minority (28%) of the vein grafts actually
decreased in size during this time frame (Fig 1, B). Impor-
tantly, loss of vein graft lumen size – negative remodeling –
during the first month was associated with earlier loss of
primary patency compared to those veins which underwent
luminal dilation. Therefore, it appears that the ability of
vein grafts to adequately dilate in the early period of im-
plantation is critical to ensure long-term patency. Not
surprisingly, shear stress correlated with early vein graft
lumen remodeling (Fig 1, C).10 Those with higher initial
shear stress dilated to a greater extent than those with less.
Taken together, these data indicate that laminar shear
stress acting through endothelium-dependent mechanisms
not only attenuates the development of over-exuberant IH,
but also influences vein graft lumen caliber regulation;
perhaps through common mediators such as NO, prosta-
noids, or hyperpolarizing factors.22,50,54,55,90
THE INFLUENCE OF INFLAMMATION
It has long been recognized that the implantation of a
vein in the arterial circulation is accompanied by a local
inflammatory response within the vein graft wall.27,91 But
the effects of systemic inflammation on the incidence of
vein graft stenosis is unknown and has only recently been
investigated in a cohort of patients undergoing lower ex-
tremity revascularization exclusively with autogenous con-
structs.92,93 In this study, three biomarkers of inflamma-
tion, high sensitivity C reactive protein (hs-CRP), serum
amyloid A (SAA), and fibrinogen were examined. While all
three were associated with the severity of PAD at the time
of presentation, with diabetes and renal failure, only hs-
CRP was found to be independently associated with ad-
verse events following bypass surgery, most of which were
vein-graft related.92
Among all inflammatory markers, the hs-CRP test is
the most validated, most widely available, and the only test
endorsed by the American Heart Association (AHA) and
Center for Disease Control as a cardiovascular risk mar-
ker.94 The AHA has determined that the hs-CRP test is
appropriate for patients with intermediate risk of cardiovas-
cular events and that values of 0-1 mg/L, 1-3 mg/L, and
3 mg/L would place patients in low, medium, and high-
risk categories, respectively. However, PAD is considered
ed fro
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are already considered high risk. Indeed, patients undergo-
ing lower extremity bypass surgery have a median hs-CRP
(3.25 mg/L) and, therefore, the AHA guidelines would
not be appropriate for this population.92 Rather, a cutoff
value of hs-CRP at 5 mg/L has more potent discriminating
ability with respect to adverse outcomes than hs-CRP
placed in tertiles, according to the AHA recommendations,
or another cutoff value.
It is still unclear whether CRP is simply a marker of
inflammation or a biomodulator of vein graft biology.
However, vein grafts in patients with high CRP do not
dilate as much as would be expected to shear stress.93
Dichotomizing patients undergoing bypass surgery with
autogenous vein by preoperative plasma CRP concentra-
tion, individuals with high CRP levels (5 mg/L) had
significantly less vein graft luminal dilation in the first
month after surgery compared to patients with CRP below
5 mg/L, 10% vs 37% (Fig 2).93 Further, the significant
positive correlation between shear stress and vein graft
luminal remodeling was no longer present in the individu-
als with higher levels of CRP. Hence, patients with high
levels of systemic inflammation have impaired ability to
positively remodel vein grafts, possibly by impairing endo-
thelial function. These studies are ongoing and the conten-
tion that inflammation, per se, can be used as a surrogate
biomarker for graft-specific failure remains to be proven.
However, many lines of evidence suggest that systemic
inflammation impairs endothelial function in patients with
PAD with significant clinical consequences. A C-reactive
protein has been shown to be associated with impaired
Fig 1. A, While the mean bypass graft lumen increase
B, Considerable variability exists between individual graf
stress at the time of implantation. D, Temporally distinc
between 1 and 3 months following implantation. Adaptbrachial artery flow mediated, endothelium dependent,vasodilation (FMD) in patients with PAD.95-97 Further, in
a cohort of patients undergoing vascular surgery, impaired
FMD has been shown to be independently associated with
adverse 30-day cardiovascular outcomes.98,99 Whether or
not intensive perioperative reduction of inflammation such
as with high-dose statin therapy would improve clinical
outcomes in this population, remains to be studied.
ENDOTHELIAL FUNCTION
Animal studies have demonstrated that veins are capa-
ut 22% over the first 6 months following implantation.
Early luminal remodeling is correlated with initial shear
luminal remodeling, the vein graft significantly stiffens
m Reference 10.
Fig 2. Vein graft lumen change (percent) from implantation to 1
month in a population undergoing lower extremity bypass grafting
for arterial occlusive disease. Luminal measurements were made
with high resolution M-mode ultrasound at the same location of
the vein graft for the operative and the 1 month assessment. By
dichotomizing the population by baseline plasmaCRP levels above
and below 5 mg/L, disparate early luminal remodeling patterns of
the vein graft become apparent, 37% vs 10%, P  .0072. Thus,
patients with high levels of systemic inflammation have impaired
ability to positively remodel vein grafts, adapted from Reference 93.s abo
ts. C,
t fromble of relaxation and contraction to vasoactive mediators
o vei
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The thinner media or the histologic arrangement of SMCs
and fibrous protein may be responsible. Vascular responses of
the human great saphenous vein (GSV) to vasoactive media-
tors has been studied using acetylcholine (Ach) or the calcium
ionophore A23187 to elicit endothelium-dependent vasodi-
lation.105-107 In general, the GSV can generate as much
contractile force in response to phenylephrine as the internal
mammary artery – about 8 to 10 grams. However, precon-
tracted GSVs exhibit variable relaxation with Ach and a
more pronounced relaxation to A23187.105,106
However, the underlying hypothesis that vein graft
endothelial function is a critical regulator of final luminal
caliber, and ultimately patency, remains to be proven. Veins
excised during redo coronary bypass grafting108 or during
revision of lower extremity vein graft stenosis109 have dem-
onstrated altered smooth muscle cell contractility and the
absence of relaxation to Ach.105,108,109 However, these
specimens were diseased and the clinical relevance is uncer-
tain. Ku et al110 studied functioning vein grafts with patent
lumens that were 7 months to 12 years in age excised from
patients undergoing heart transplantation. Several impor-
tant observations are noteworthy from this study. First, all
vein grafts exhibited vasorelaxation to Ach though with
considerable variability,9% to65% of the precontracted
state existed between different grafts. Second, there was
significant variability even within a single vein-graft seg-
ment indicating local heterogeneity in NO production
Fig 3. Modes of vein graft failure. While themajority of
(12%) is diffuse. A, Represents a 6-month-old vein graft
(arrow) that was successfully treated with a vein patch
77-year-old black women undergoing angiography fo
developed diffuse intimal hyperplasia which progressed talong the course of the vein graft. And third, vein graftswith the most pronounced IH exhibited the least amount
of endothelium-dependent relaxation. These observations
suggest that a functional endothelial lining is regenerated in
human vein grafts, that it is not constant along the length of
the vein graft, and that IH is at least associated with
endothelial impairment.111
These findings may be one explanation of the focal
nature of most vein graft lesions. While diffuse IH occlusive
disease may occur in approximately 12% of vein grafts, the
majority of culprit lesions are focal and often perianasto-
motic (Fig 3).15,16,35 A focal deficiency in NO from either
pre-existing lesions, primary endothelial injury, or turbu-
lent flow with altered shear stress, may result in an area of
the graft that fails to sufficiently remodel.31,33,112-114 The
cumulative result of the relative deficiency of NO would be
increased IH,79,115 decreased remodeling,116 and possibly
an increase in collagen production,117,118 thereby stiffen-
ing the vein graft and further reducing the ability to dilate.
Hence, the wall would thicken disproportionately to the
lumen dilatation producing the clinically familiar focal ste-
nosis within a segment of the vein graft (Fig 4).
Detection of the more physiologically-relevant flow-
stimulated endothelial function has recently been tested in
vivo in a cohort of patients with mature (1 year since
implantation) femoropopliteal vein grafts that have not
undergone revision. The technique was similar to the one
employed to test brachial artery FMDwhich is known to be
endothelium-dependent and mediated by NO.119 Assess-
al hyperplasia in vein grafts is focal, a substantial minority
7-year-old white man that developed a midgraft stenosis
ioplasty. B, Represents a 4-month-old vein graft in a
tralateral limb ischemia. C, Three months later, she
n graft occlusion.intim
in a 6
ang
r conment of endothelial function by brachial artery flow-
wall
as 3
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measures small changes in brachial artery diameter in re-
sponse to an increase in blood flow. By applying an occlu-
sive blood pressure cuff over the proximal calf for 5 min-
utes, a hyperemic response (increase in blood flow and
Decrease lumen  
radius  
Near-occlusive 
intimal
hyperplasia
Marked Increase 
in wall thickness 
decrease in total 
vessel diameter
Stenotic segment
A
B
Fig 4. Histologic sections (10) of an 8-month-old
underwent open revision with a short interposition gra
implantation. A, The sections were taken approximately
marked intimal hyperplasia and has a smaller area circums
vessel diameter indicative of negative remodeling of t
adaptation patterns of a human lower extremity vein gr
postimplantation period to produce a lumen diameter to
Fig 5. Flow mediated vasodilation in mature human sa
A, Application of an occlusive blood pressure cuff (220 m
femoro-popliteal bypass grafts for 5 minutes produces an
this cohort, flow mediated, endothelium dependent vas
independent (0.4 mg sublingual nitroglycerin) dilation wshear stress) was stimulated in the leg upon its release(Fig 5). High resolution ultrasound scan and postprocess-
ing imaging software was then used to carefully measure
vein graft blood flow, shear stress, and lumen diameter
before and after the hyperemic response and, therefore,
calculate FMD in the vein graft. Hyperemia resulted in a
Increase radius,
20-25%
Minimal intimal
hyperplasia
Increase in wall 
thickness 
Increase in total 
vessel diameter,
35-45%
Preimplantation vein
Adjacent normal
graft which developed a focal midgraft stenosis and
he vein was of uniform size and caliber at the time of
from one another. The area of stenosis has developed
d by the internal elastic laminae as well as decreased total
tire vein graft. B, Theoretical normal and abnormal
Normally the lumen and wall area increase in the early
thickness ratio of about 7.
ous vein grafts demonstrates a functional endothelium.
) to the proximal calf of a cohort of patients undergoing
ase in blood flow and shear stress within the graft. B, In
ion was 5.3% and nitroglycerin mediated, endothelium
.7%.vein
ft. T
2 cm
cribe
he en
afts.phen
mHg
incre
odilat233% increase in volumetric flow through the vein graft
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we believe for the first time, that vein grafts did dilate to an
increase in blood flow. Vein graft FMD was 5.28%  3.1%
(range, 1.99-4 9.36%), for the entire cohort (Fig 5). The
specificity of NO as the mediator of this response was
established by intravenously administering the NO-inhibitor
NG L-monomethyl arginine (L-NMMA), during a sub-
sequent test which abolished the FMD response in all
vein grafts.
These studies demonstrate that vein grafts have a bio-
logically active endothelial layer which can be assessed by
noninvasive techniques. The relationship of endothelial cell
function, the extent, and timing of its recovery of function,
and patency of the vein graft remains to be seen and is an
area of ongoing investigation. It is provocative to speculate
that pharmacologic adjuncts, provided locally or remotely,
to improve endothelial function and NO availability may
decrease IH, improve remodeling, and increase vein graft
patency.
THE VEIN GRAFT WALL
While shear stress is the dominant regulator of lumen
caliber, wall tension is the more critical determinant of wall
thickness. Animal models indicate that there is a structurally
optimal lumen radius/wall thickness ratio to support arte-
rial pressure with minimal wall stress. Indeed, there is a
remarkable consistency of tension per lamellar unit of the
aortic media across diverse mammalian species from the
mouse to man.121 In a rabbit vein graft model, the ratio of
lumen radius to wall thickness (ri/h), initially very high at
the time of implantation, approached that of the normal
carotid artery by 24 weeks.56 In humans, vein graft lumen
diameter to wall thickness ratio, about 9:1 at the time of
implantation, is reduced to 7.4 at 6 months, a value close to
that of the superficial femoral artery (Table).122 Until re-
cently, accurate in vivo measurement of the vein graft wall
has been elusive. However, high-resolution 3-D MRI with
superior signal-to-noise ratio, is capable of resolving struc-
tures as small as 300 microns within the range of the vein
graft wall.8 By simultaneously measuring wall thickness and
lumen radius at 1 and 6 months postimplantation, a very
strong correlation existed between luminal enlargement
and total vessel enlargement.120 The equation 	LD 
0.62(	OD) to 0.02, where LD is lumen diameter and OD
is total vein graft outer diameter, relates changes in luminal
diameter to changes in total vessel diameter. This linear
Table. Remodeling of human saphenous vein graft,
0-6 month
Implantation 6 months SFA
LD (mm) 3.7 4.5 6.8
Stiffness (Mdynes/cm) 2.0 3.3 1.7
Wall thickness (m) 410 610 870
LD/WT 9.0 7.4 7.8
LD, Lumen diameter; WT, wall thickness.regression equation relates what should happen to thelumen of a normal patent bypass graft given a measurable
change in the vein graft wall. For example, a 22% increase in
the lumen diameter should be accompanied by a 35%
increase in the outer diameter of the vein graft. A slope
substantially less than 0.62 would indicate excessive thick-
ening of the wall or insufficient lumen dilation.
Systematic studies of human vein grafts with aid of
modern high-resolution imaging technology provide in-
sight into vein adaptation in the arterial environment. It has
become clear that vein remodeling constitutes changes in
luminal and total vessel diameter. The forces and flows
responsible for these changes are becoming clear but other
factors are involved as well. As can be seen in Fig 4,
segments of a vein graft with near occlusive IH also had a
smaller total vessel diameter compared with a normal adja-
cent segment. Therefore, in this particular case, the stenosis
was due to a combination of negative remodeling and IH.
Further studies are needed in this important area.
CLINICAL SCIENCE
Translational advances notwithstanding, there has been
much improvement in the clinical sciences of vein graft
outcomes. Hypothesis-driven, multi-centered trials,6 na-
tional databases with quality measures,123 and comparative
effectiveness trials124 have replaced single-center retrospec-
tive studies and promise to be more reflective of real world
practice. These trials, when carefully conducted, can poten-
tially bridge the bench to bedside translational gulf and
careful observations of the results can often be hypothesis
generating. For example, PREVENT III alone has resulted
in 10 published manuscripts of outcomes in patients with
CLI examining quality measures, resource utilization, racial
disparities, technical considerations, and risk estimation
scores.6,89,125-132
Long-term results from the Bypass vs Angioplasty in
Severe Ischemia of the Leg (BASIL) trial emphasize that
the more durable reconstruction with a vein graft translates
into improved outcomes compared to less invasive alterna-
tives.124,133 However, technical factors such as smaller
diameter and longer bypass grafts experience more graft-
related events (GRE), and GREs result in decreased quality
of life (QoL) and increased resource utilization emphasiz-
ing the importance of patency as an outcome mea-
sure.89,128 A priori identification of vulnerable grafts
through the use of biochemical and imaging biomarkers
may provide an opportunity for targeted therapy or, at the
very least, identify patients who would benefit from a more
intensive surveillance program. Surrogate endpoints such
as novel methods of detection of vein endothelial health
(function), IH kinetics, and normal and abnormal remod-
eling patterns will improve our understanding of the mech-
anisms of action for the next biologic or new clinical entity
to emerge to improve vein graft patency.
Results from clinical trials may have significant biologic
implications. For example, gender and racial disparity, of-
ten overlooked in single-centered studies due to small
sample size, can be examined in multicentered cohorts.
While it is well known that PAD disproportionately affects
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In the PREVENT III database, patients with black race and
female gender were at increased risk of graft occlusion and
had inferior limb salvage, but there were no differences in
primary patency compared with white patients.125 This
finding suggests that the disease process is more aggressive,
possibly more diffuse, and, therefore, lower rates of graft
salvage by revisions once IH stenosis developed or surgeons
were quicker to abandon the graft. An altered biologic
healing response to the implanted graft, possibly through
increased inflammation, altered thrombogenicity, or differ-
ential endothelial cell responses may be responsible.134-138
Thus observations from clinical trials such as these can
directly stimulate basic scientific efforts.
CONCLUSION
Beyond the risk of limb loss, decreased graft patency
results in increased resource utilization128 and significantly
impacts QoL.127 Our current pharmacopoeia has not made
any significant impact on the natural history of vein graft
stenosis emphasizing the need for a better mechanistic
understanding of graft failure.139 Animal models andmath-
ematical constructs should incorporate structural as well as
functional changes of the maturing vein graft. Understand-
ing the relative contributions of IH and remodeling are not
simply academic, as molecular therapeutics targeted at IH
will likely not improve remodeling. Multidisciplinary trans-
lational research programs leveraging recent advances in
biomedical imaging, molecular technology, and genetic
engineering will likely dramatically increase our under-
standing of this vexing problem.
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